In these early clinical trials bevacizumab showed antitumor action in breast, colon, and lung cancer and identified a variety of toxicities, together with bleeding, thrombosis, hypertension, and proteinuria. The extension study was initiated in reaction to requests from patients and investigators. All patients who done ≥ one 12 months of https://haimc431kub1.wikigiogio.com/user